Overview

Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer

Status:
Recruiting

Trial end date:
2026-09-01

Target enrollment:

Participant gender:

Summary

We will conduct a Phase I trial testing whether local cystoscopic injection of tremelimumab into the bladder wall in combination with systemic administration of durvalumab in localized bladder cancer will stimulate an effective anti-tumour immune response with minimal systemic immune response and clinical toxicity.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of British Columbia

Treatments:

Tremelimumab